SLS Stock Rises 2% Overnight as Healthcare Execs Tout AML Drug GPS as 'Game Changer'
According to LinkedIn comments, healthcare executives publicly praised Sellas Life Sciences' galinpepimut-S (GPS) as a 'game changer' for acute myeloid leukemia (AML) treatment overnight on August 30, driving SLS stock 2% higher. Michael Anglestein, a senior respiratory biologics sales specialist at
SLS3.61%
GateNews·08-31 04:37
